Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, open, multicenter phase II clinical trial, proof of concept, to evaluate efficacy and safety of Icatibant in hospitalized patients with SARS-COV-2 (COVID-19) without assisted ventilation compared with standard care

X
Trial Profile

Randomized, open, multicenter phase II clinical trial, proof of concept, to evaluate efficacy and safety of Icatibant in hospitalized patients with SARS-COV-2 (COVID-19) without assisted ventilation compared with standard care

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icatibant (Primary) ; Antipyretics; Dexamethasone; Low molecular weight heparins; Remdesivir
  • Indications COVID 2019 infections; COVID-19 pneumonia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms HUB-MdI-ICAT-COVID-201; ICAT-COVID
  • Most Recent Events

    • 04 Jan 2023 Results assessing efficacy of Three day icatibant on top of standard care in patients with COVID-19 pneumonia published in the Clinical Infectious Diseases
    • 02 Aug 2022 Status changed from recruiting to completed.
    • 12 Apr 2022 Study design published in the Trials
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top